Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.
Jeongjun KimJinho ChoiHwankyu KangJiye AhnJane HutchingsChristo van NiekerkDongsik ParkJaeseung KimYeejin JeonKiyean NamSoyoung ShinBeom Soo ShinPublished in: Antimicrobial agents and chemotherapy (2021)
Telacebec (Q203) is a potent drug candidate under clinical development for the treatment of drug-naïve and drug-resistant tuberculosis. The first-in-human randomized, placebo-controlled, double-blind, dose-escalation Phase 1A trial (Q203-TB-PI-US001) was conducted to evaluate the safety, tolerability, and pharmacokinetics of telacebec. A total of 56 normal, healthy, male and female subjects (42 active and 14 placebo) were enrolled in the study. The doses of telacebec were 10 mg (Cohort 1), 30 mg (Cohort 2), 50 mg (Cohort 3), 100 mg (Cohort 4), 200 mg (Cohort 5), 400 mg (Cohort 6), and 800 mg (Cohort 7) in a fasted state. Subjects participating in Cohort 4 were also enrolled in Cohort 8 to investigate the food effect on the pharmacokinetics of telacebec after a high-fat meal. In all subjects dosed with telacebec (10 - 800 mg), telacebec was well tolerated and did not lead to any significant or serious adverse events. Following a single oral administration of telacebec (10 - 800 mg), telacebec plasma concentration reached the maximal plasma concentration (Cmax) in average 2.0 - 3.5 h and showed multi-exponential decline thereafter. The area under the plasma concentration vs. time curve (AUC) was approximately dose-proportional. A significant increase in plasma concentrations was observed in the fed condition compared with the fasted condition with the geometric mean ratio of 3.93 for Cmax. Moderate delay in Tmax (4.5 h) was also observed in the fed condition. These results, combined with the demonstrated activity against drug-sensitive and multidrug-resistant Mycobacterium tuberculosis, support further investigation of telacebec for the treatment of tuberculosis.
Keyphrases
- double blind
- placebo controlled
- mycobacterium tuberculosis
- drug resistant
- multidrug resistant
- phase iii
- clinical trial
- open label
- study protocol
- phase ii
- escherichia coli
- randomized controlled trial
- radiation therapy
- risk assessment
- squamous cell carcinoma
- pulmonary tuberculosis
- gram negative
- acinetobacter baumannii
- adverse drug
- hiv aids
- replacement therapy
- rectal cancer